Production (Stage)
BioXcel Therapeutics, Inc.
BTAI
$1.39
$0.021.46%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.85M | 2.27M | 2.28M | 2.40M | 1.76M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.85M | 2.27M | 2.28M | 2.40M | 1.76M |
| Cost of Revenue | 2.08M | 2.14M | 2.03M | 1.37M | 1.33M |
| Gross Profit | -226.00K | 122.00K | 250.00K | 1.04M | 424.00K |
| SG&A Expenses | 26.93M | 34.49M | 40.00M | 56.66M | 73.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.59M | 67.07M | 76.49M | 107.02M | 142.34M |
| Operating Income | -50.74M | -64.80M | -74.22M | -104.61M | -140.59M |
| Income Before Tax | -40.06M | -59.60M | -71.00M | -107.83M | -153.05M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.06 | -59.60 | -71.00 | -107.83 | -153.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.06M | -59.60M | -71.00M | -107.83M | -153.05M |
| EBIT | -50.74M | -64.80M | -74.22M | -104.61M | -140.59M |
| EBITDA | -50.43M | -64.50M | -73.91M | -104.30M | -140.27M |
| EPS Basic | -13.52 | -25.91 | -34.43 | -56.88 | -82.92 |
| Normalized Basic EPS | -7.87 | -15.61 | -20.94 | -33.91 | -50.40 |
| EPS Diluted | -13.52 | -25.91 | -34.43 | -56.88 | -82.92 |
| Normalized Diluted EPS | -7.87 | -15.61 | -20.94 | -33.91 | -50.40 |
| Average Basic Shares Outstanding | 13.04M | 10.13M | 8.93M | 8.11M | 7.42M |
| Average Diluted Shares Outstanding | 13.04M | 10.13M | 8.93M | 8.11M | 7.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |